The Acyclic Carbon Or Acyclic Carbon Chain Is Further Unsubstituted Or Alkyl Substituted Only (e.g., Tryptophane, Etc.) Patents (Class 548/496)
  • Publication number: 20150141513
    Abstract: The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of neurological degenerative disorders and neurological diseases may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of narcolepsy, shift work sleep disorder, and as an adjunct treatment for obstructive sleep apnea/hypopnea, hypersomnias, like idiopathic hypersomnia, Psychiatric/neurodegenerative disorders, ADHD, Psychiatric/neurodegenerative disorders, Depersonalization disorder, Cognitive enhancement, Fatigue, Post-chemotherapy cognitive impairment and weight loss.
    Type: Application
    Filed: April 19, 2013
    Publication date: May 21, 2015
    Inventor: Mahesh Kandula
  • Publication number: 20150126462
    Abstract: The present invention relates to a new pharmaceutical composition containing nicotinic acid, nicotinamide, tryptophanor related compounds for positively influencing the intestinal microbiota. In certain embodiments, the pharmaceutical composition is partially or entirely released into the small intestine or large intestine.
    Type: Application
    Filed: June 14, 2013
    Publication date: May 7, 2015
    Applicant: CONARIS RESEARCH INSTITUTE AG
    Inventors: Georg Waetzig, Dirk Seegert
  • Publication number: 20150094465
    Abstract: The present disclosure is directed to compounds, diagnostic agents, and related methods. In some cases, methods for treating patients are provided. More specifically, the disclosure provides compounds, diagnostic agents, and kits for detecting and/or imaging and/or monitoring elastin rich tissues. In addition, the disclosure provides methods of detecting and/or imaging and/or monitoring the presence of coronary plaque, carotid plaque, iliac/femoral plaque, aortic plaque, renal artery plaque, plaque of any arterial vessel, aneurism, vasculitis, other diseases of the arterial wall, and/or damage or structural changes in ligaments, uterus, lungs or skin, as indicated by changes in total vessel wall area, internal lumen size, and exterior arterial perimeter.
    Type: Application
    Filed: September 2, 2014
    Publication date: April 2, 2015
    Applicant: Lantheus Medical Imaging, Inc.
    Inventors: Richard R. Cesati, Thomas D. Harris, Simon P. Robinson, Richard J. Looby, Edward H. Cheesman, Padmaja Yalamanchili, David S. Casebier
  • Publication number: 20150011778
    Abstract: This disclosure teaches the novel use of trifluoroacetamide for N-terminal protection. The disclosure also teaches novel compositions and chemical structures associated therewith. These methods and compositions are useful for site-specific methylation of peptide backbone amides, performed, for example, to modulate the pharmacokinetic properties of peptide drugs.
    Type: Application
    Filed: February 19, 2013
    Publication date: January 8, 2015
    Inventors: Scott Lokey, Rushia Turner
  • Publication number: 20140288119
    Abstract: This invention provides a compound having the structure: wherein R1 is H, halogen, —NR5R6, —NR5—C(?O)—R6, —NH—C(?O)—OR7, —OR7, —NO2, —CN, —SR7, —SO2R7, —CO2R7, CF3, —SOR7, —POR7, —C(?S)R7, —C(?O)—NR5R6, —CH2—C(?O)—NR5R6, —C(?NR5)R6, —P(?O)(OR5)(OR6), —P(OR5)(OR6), —C(?S)R7, C1-5 alkyl, C2-5 alkenyl, C2-5 alkynyl, aryl, heteroaryl, or heterocyclyl, wherein R5, R6, and R7 and are each, independently, H, C1-5 alkyl, C2-5 alkenyl, C2-5 alkynyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; m is an integer from 0 to 2; R2 and R3 are each, independently, H, halogen, —NH2, —CX3, —C(?O)OR8, C(?O)R8, —C(?O)NR9R10, C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, heteroalkyl, aryl, heteroaryl, or heterocyclyl; wherein X is Cl, Br, or F; R8, R9 and R10 are each, independently, H, C1-5 alkyl, C2-5 alkenyl, C2-5 alkynyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; Q is —Ar1—Z— or —Z—Ar1—Z—, wherein Ar1 is aryl or heteroaryl; and each occurrence of Z is independently present or
    Type: Application
    Filed: October 3, 2012
    Publication date: September 25, 2014
    Applicants: The Trustees of Columbia University in the City of New York, SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH
    Inventors: Ronald Breslow, Paul A. Marks
  • Publication number: 20140243282
    Abstract: The present invention relates to novel drug conjugates, where in two drugs are linked together through an appropriate linker having at least two functional groups capable of forming covalent bond with drugs D1 and D2. The invention also relates to developing novel compositions, methods for their preparation and their use in treating various disease conditions.
    Type: Application
    Filed: December 12, 2011
    Publication date: August 28, 2014
    Inventor: Satish Reddy Kallam
  • Patent number: 8816076
    Abstract: The present invention relates to novel aryl urea derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of the N-formyl peptide receptor like-1 (FPRL-1) receptor.
    Type: Grant
    Filed: August 14, 2013
    Date of Patent: August 26, 2014
    Assignee: Allergan, Inc.
    Inventors: Richard L. Beard, Tien T. Duong, John E. Donello, Veena Viswanath, Michael E. Garst
  • Publication number: 20140221231
    Abstract: A method is described that uses ROR gamma t, or ROR alpha to diagnose rosacea and/or to screen inhibitors of Th17 differentiation, notably in inhibiting ROR gamma t or ROR alpha. Also described is a method of using these screened inhibitors in rosacea treatment.
    Type: Application
    Filed: June 25, 2012
    Publication date: August 7, 2014
    Applicant: Galderma Research & Development
    Inventor: Martin Steinhoff
  • Patent number: 8765953
    Abstract: The present invention relates generally to alkyne containing pharmaceutical agents, and in particular, to phenylethynyl-thiophene based metalloprotease inhibitor compounds. More particularly, the present invention provides a new class of MMP inhibiting compounds that exhibit increased potency, metabolic stability and/or reduced toxicity in relation to currently known MMP inhibitors for the treatment of pain and other diseases such as cancer. Additionally, the present invention relates to methods for treating pain in a patient comprising administering to the patient a pain-reducing effective amount of a present compound.
    Type: Grant
    Filed: December 21, 2009
    Date of Patent: July 1, 2014
    Assignee: Aquilus Pharmaceuticals, Inc.
    Inventor: Irving Sucholeiki
  • Publication number: 20140107027
    Abstract: Methods, compounds, pharmaceutical compositions and kits are described for treating or preventing amyloid-related disease.
    Type: Application
    Filed: December 18, 2013
    Publication date: April 17, 2014
    Applicant: BHI LIMITED PARTNERSHIP
    Inventors: Xianqi Kong, David Migneault, Isabelle Valade, Xinfu Wu, Francine Gervais
  • Patent number: 8697680
    Abstract: The present invention provides pharmaceutical compositions comprising substituted 1,4 naphthoquinones that are effective in preventing oligomerization of beta amyloid and subsequent pathologies associated with amyloid fibrils. These compositions are useful for the treatment of disease involving amyloidogenesis including neurodegenerative diseases such as Alzheimer's Disease or senile dementia. Particularly effective compositions comprise 1,4 naphthoquinones substituted with an amino acid residue selected from a heterocyclic or aromatic amino acid.
    Type: Grant
    Filed: September 6, 2009
    Date of Patent: April 15, 2014
    Assignee: Ramot At Tel Aviv University Ltd.
    Inventors: Roni Scherzer, Ehud Gazit, Daniel Segal
  • Publication number: 20140066361
    Abstract: Peptides useful as angiotensin converting enzyme inhibitors are provided. Also provided are compositions comprising one or more of the peptides and methods for preventing, treating and/or diminishing one or more syndromes associated with angiotensin converting enzyme by using the peptides.
    Type: Application
    Filed: September 6, 2012
    Publication date: March 6, 2014
    Applicant: FOOD INDUSTRY RESEARCH AND DEVELOPMENT INSTITUTE
    Inventors: YI-HONG CHEN, HSIANG-LING LAI, SHIAO-CHENG CHUANG, CHIEN-TI CHANG, MING-YU HUNG, YU-HUI LIU, SU-ER LIOU, FU-NING CHIEN, CHU-CHIN CHEN
  • Publication number: 20140039200
    Abstract: The present invention relates to chiral ligands deriving from ?- and ?-amino acids, and from metal complexes formed from the same. The ligands are useful with catalytic gold complexes, particularly Au(I) complexes.
    Type: Application
    Filed: March 30, 2012
    Publication date: February 6, 2014
    Applicant: The University of Sussex
    Inventors: Eddy Michel Elie Viseux, Christopher Gallop, Mariusz Bobin
  • Patent number: 8642639
    Abstract: The present invention relates to the use of L-tryptophan and a peripheral degradation inhibitor of L-tryptophan for the manufacture of a medicament for prevention or therapy of pain, depressions, sleeping disorders and other serotonin dependent diseases of the CNS, wherein L-tryptophan is present in a retarded and the peripheral degradation inhibitor is present in a non-retarded formulation.
    Type: Grant
    Filed: August 12, 2005
    Date of Patent: February 4, 2014
    Assignee: Kamprad KG
    Inventor: Joachim Kamprad
  • Publication number: 20130331570
    Abstract: The present invention relates to novel aryl urea derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of the N-formyl peptide receptor like-1 (FPRL-1) receptor.
    Type: Application
    Filed: August 14, 2013
    Publication date: December 12, 2013
    Applicant: Allergan, Inc.
    Inventors: Richard L. Beard, Tien T. Duong, John E. Donello, Veena Viswanath, Michael E. Garst
  • Publication number: 20130296281
    Abstract: The invention relates to aryl and heteroaryl substituted compounds of Formula (I), and pharmaceutically acceptable salts, prodrugs, or solvates thereof, wherein G, R1, and Z1-Z5 are defined as set forth in the specification. The invention is also directed to the use of compounds of Formula (I) to treat a disorder responsive to the blockade of sodium channels. Compounds of the present invention are especially useful for treating pain.
    Type: Application
    Filed: June 16, 2011
    Publication date: November 7, 2013
    Applicant: Purdue Pharma L.P.
    Inventors: Donald J. Kyle, Chiyou Ni, Laykea Tafesse, Jiangchao Yao
  • Publication number: 20130289090
    Abstract: Substituted indole derivatives of formula (I) wherein the radicals have e.g. the following meaning: R1 is hydrogen, C1-6-alkyl, R2 is hydrogen, —C1-6-alkyl or cycloC3-12-alkyl; R3 is OR R4 is hydrogen or halogen, R5 is hydrogen, —C1-6-alkyl R6 is hydrogen, —C1-6-alkyl R is hydrogen or —C1-6-alkyl; X is a group —C(O)CH2— or —CH?CH—; R7 is hydrogen are potent inhibitors of Abeta peptide polymerization and can be used for the treatment of e.g. Alzheimers disease or ocular disorders.
    Type: Application
    Filed: October 27, 2011
    Publication date: October 31, 2013
    Applicant: MERZ PHARMA GMBH & CO. KGAA
    Inventor: Ulrich Abel
  • Publication number: 20130225512
    Abstract: Dipeptide analogs comprising a tryptophan (Trp) moiety coupled to a beta-sheet breaker moiety derived from alpha-aminoisobutyric acid (Aib) are disclosed. The dipeptide analogs exhibit an improved performance in inhibiting amyloid fibril formation, as compared to previously described dipeptides. Compositions containing the dipeptide analogs and uses thereof in treating amyloid-associated diseases and disorders are also disclosed.
    Type: Application
    Filed: November 15, 2011
    Publication date: August 29, 2013
    Applicant: Merz Pharma GmbH & Co. KGaA
    Inventors: Ehud Gazit, Yaniv Amir, Ludmila Buzhansky, Ulrich Abel, Anat Frydman-Marom
  • Publication number: 20130203085
    Abstract: The invention relates to an antigenic structure that contains a tryptophan epitope, characterised in that said structure is made up of a tryptophan pattern W or a peptide of 3 or 4 amino acids comprising a pattern W, coupled with glutaraldehyde. The invention can he used for screening trypanosomiasis in humans or animals.
    Type: Application
    Filed: April 13, 2011
    Publication date: August 8, 2013
    Applicant: Institut de Recherche pour le Developpment (IRD)
    Inventors: Philippe Holzmuller, Silla Semballa, Philippe Vincendeau, Gerard Cuny
  • Publication number: 20130158021
    Abstract: Described herein are compounds and compositions characterized, in certain embodiments, by conjugation of various groups, such as lipophilic groups, to an amino or amide group of an amino acid, a linear or cyclic peptide, a linear or cyclic polypeptide, or structural isomer thereof, to provide compounds of the present invention, collectively referred to herein as “APPLs”. Such APPLs are deemed useful for a variety of applications, such as, for example, improved nucleotide delivery. Exemplary APPLs include, but are not limited to, compounds of Formula (I), (II), (III), (IV), (V), and (VI), and salts thereof, as described herein: wherein m, n, p, R?, R1, R2, R3, R4, R5, R8, Z, W, Y, and Z are as defined herein.
    Type: Application
    Filed: October 26, 2012
    Publication date: June 20, 2013
    Applicant: Massachusetts Institute of Technology
    Inventor: Massachusetts Institute of Technology
  • Publication number: 20130108560
    Abstract: A thin film composition for oral administration that adheres to and dissolves in a mouth of a user, wherein the thin film is a single layered water-soluble solid comprising at least one D-amino acid contained in a plurality of hydrophobic carriers dispersed throughout the thin film. The hydrophobic carriers comprise oil and the composition further comprises a phospholipid, an emulsifier, and a water soluble polymer. The preferred D-amino acids are D-leucine, D-tryptophan, D-methionine, and D-tyrosine. A method of reducing dental plaque in a subject entails placing the thin film composition contemplated herein into a mouth of the subject.
    Type: Application
    Filed: November 1, 2012
    Publication date: May 2, 2013
    Inventors: Robert Davidson, Eric Allen, Ed Maliski
  • Publication number: 20130071439
    Abstract: Methods of treating or reducing biofilms, treating a biofilm-related disorder, and preventing biofilm formation using D-amino acids are described.
    Type: Application
    Filed: January 10, 2011
    Publication date: March 21, 2013
    Applicant: PRESIDENT AND FELLOWS OF HARVARD COLLEGE
    Inventors: Richard Losick, Jon Clardy, Roberto Kolter, Illana Kolodkin-Gal, Diego Romero, Shugeng Cao
  • Publication number: 20130045930
    Abstract: The present invention relates to crystalline forms of the mono-sodium salt of D-isoglutamyl-D-tryptophan, pharmaceutical compositions comprising them, their use in the treatment of various diseases and conditions, and processes for their preparation. In particular, the present invention relates the crystal modification 2 (polymorphic form I) of the mono-sodium salt of D-isoglutamyl-D-tryptophan.
    Type: Application
    Filed: June 7, 2012
    Publication date: February 21, 2013
    Applicant: APOTEX TECHNOLOGIES INC.
    Inventors: Tim Fat TAM, Blaise N'ZEMBA, Regis LEUNG-TOUNG, Yingsheng WANG, Yanqing ZHAO, Lily YU
  • Publication number: 20130045929
    Abstract: The present invention relates to crystalline forms of the mono-sodium salt of D-isoglutamyl-D-tryptophan, pharmaceutical compositions comprising them, their use in the treatment of various diseases and conditions, and processes for their preparation. In particular, the present invention relates the crystal modification 1 (polymorphic form F) of the mono-sodium salt of D-isoglutamyl-D-tryptophan.
    Type: Application
    Filed: June 7, 2012
    Publication date: February 21, 2013
    Applicant: APOTEX TECHNOLOGIES INC.
    Inventors: Tim Fat TAM, Blaise N'ZEMBA, Regis LEUNG-TOUNG, Yingsheng WANG, Yanqing ZHAO, Lily YU
  • Publication number: 20120329716
    Abstract: The instant invention relates to peptides obtained from the enzymatic hydrolysis of yellow pea seed proteins that are capable of lowering the blood pressure and reducing the effects of kidney disease in a subject b\ inhibiting or reducing the affinity of the enzymes in the renin-angiotensin system for their substrates, specifically renin, to compositions comprising said peptides and to uses thereof.
    Type: Application
    Filed: October 28, 2010
    Publication date: December 27, 2012
    Inventors: Rotimi Aluko, Jianping Wu, Harold Aukema
  • Publication number: 20120329846
    Abstract: Disclosed is an agent for use in the treatment or prevention of inflammatory bowel disease. Also disclosed is an agent for inhibiting the production of TNF-?. A therapeutic or prophylactic agent for inflammatory bowel disease comprising at least one amino acid selected from the group consisting of lysine, histidine, phenylalanine, methionine, tryptophan, glutamine, glycine, cysteine, cystine and threonine, the amino acid being administered at a dose of 0.1 to 4000 mg/kg per day; and a TNF-? production inhibitor comprising an amino acid selected from the group consisting of histidine, phenylalanine and tryptophan, the amino acid being administered at a dose of 0.1 to 4000 mg/kg per day.
    Type: Application
    Filed: March 27, 2012
    Publication date: December 27, 2012
    Applicant: Ajinomoto Co., Inc.
    Inventors: Hideki Matsumoto, Tomohisa Okutsu, Tomoko Takeda, Hideki Suzuki, Tetsuo Yano, Masaki Hashimoto, Miho Ono, Manabu Suzuki
  • Publication number: 20120302719
    Abstract: New bioresorbable polymers are synthesized from monomer analogs of natural metabolites In particular, polymers are polymerized from analogs of amino acids that contribute advantageous synthesis, processing and material properties to the polymers prepared therefrom, including particularly advantageous degradation profiles
    Type: Application
    Filed: May 29, 2012
    Publication date: November 29, 2012
    Applicant: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY
    Inventors: Joachim B. Kohn, Durgadas Bolikal
  • Publication number: 20120129800
    Abstract: The present invention concerns an agent for prevention and treatment of pityriasis. The agent according to the present invention comprises at least one transaminase inhibitor effectively inhibiting the transamination process which is of pathogenetic relevance for the disease, prevents a recurrence of the disease and which protects the human skin flora. Upon release into the environment, no resistances are induced in other fungi.
    Type: Application
    Filed: January 14, 2010
    Publication date: May 24, 2012
    Applicant: Justus-Liebig-Universitat Giessen
    Inventor: Peter Mayser
  • Publication number: 20120120551
    Abstract: A method of fabricating a device is disclosed. The method comprises coating a solid structure by nanostructures selected from the group consisting of peptides and amino acids, under conditions that at least partially prevent assembly of the nanostructures into supramolecular structures.
    Type: Application
    Filed: November 16, 2011
    Publication date: May 17, 2012
    Applicant: Ramot at Tel-Aviv University Ltd
    Inventors: Peter BEKER, Gil Rosenman
  • Publication number: 20120107835
    Abstract: A method for detecting ?-amyloid using an amino acid dimer instead of a secondary antibody binding to the ?-amyloid primary antibody in an immunoassay based on an antigen-antibody reaction, and a kit for detecting ?-amyloid including the dimer. The method is advantageous in that the dimer has good properties in stability, availability, and storage compared to antibodies and that it can detect various ?-amyloids by using one kind of antibody, and thus may be effectively used in early diagnosis and research of Alzheimer's disease.
    Type: Application
    Filed: October 7, 2011
    Publication date: May 3, 2012
    Applicant: ELECTRONICS AND TELECOMMUNICATIONS RESEARCH INSTITUTE
    Inventor: Hyo Bong Hong
  • Publication number: 20120052110
    Abstract: Provided herein are compositions and methods that inhibit expression of Adam12 gene products, such as ADAM12 mRNA and/or ADAM12 polypeptides, as a therapeutic approach for the treatment of, or promotion of healing of, wounds.
    Type: Application
    Filed: August 4, 2011
    Publication date: March 1, 2012
    Applicant: Hospital for Special Surgery
    Inventors: Marjana TOMIC, Carl Peter Blobel, Asheesh Harsha
  • Patent number: 8124585
    Abstract: The invention relates to a method of controlling feelings of pain in infants or diseased or elderly persons using a complete nutrition or a nutritional supplement. The method comprises administering increased levels of folic acid, vitamin B6 and vitamin B12 or their functional equivalents.
    Type: Grant
    Filed: May 10, 2005
    Date of Patent: February 28, 2012
    Assignee: N.V. Nutricia
    Inventors: Robert Johan Joseph Hageman, Jacob Geert Bindels
  • Publication number: 20110319387
    Abstract: The invention relates to a compound of the following formula (I), or to a pharmaceutically acceptable salt thereof or to a stereoisomer or mixture of stereoisomers at any proportions, where: X1 is a CH2 or C?O group; X2 is a linear saturated or unsaturated carbohydrate chain with 8 to 24 carbon atoms; R1 is a hydrogen atom or an OH or (C1-C6)alkoxy group such as methoxy; and R2 is a CH3 or CH2OR3 group, with R3 being a hydrogen atom or a (C1-C6)alkyl, CO—(C1-C6)alkyl or NH—(C1-C6)alkyl group. The invention also relates to the use of said compound as a drug, in particular for treating neurodegenerative diseases, and to a method for preparing same.
    Type: Application
    Filed: March 2, 2010
    Publication date: December 29, 2011
    Applicant: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
    Inventors: Fanny Schmidt, Bruno Figadere, Rita Raisman-Vozari, Pierre Champy
  • Publication number: 20110311505
    Abstract: This invention is related to preparation of photosensitive ruthenium based aminoacid monomers and oligomers, aminoacid monomer-protein cross-linking using photo sensitat ion and conjugation on micro and nano-structures by ruthenium-chelate based monomers. Its vast range biotechnolgy applications of multifunctional, biocompatible, stabilE and specific micro and nanobio-conjugates, which will stand-alone or simultaneously enable (i) both purification and determination, (ii) both targeting and imaging and theranostics and (iii) catalysis and determination. The construction and method of preparation is applicable to silica materials, superparamagnetic particles, QDs, CNTs, Ag/Au nanoparticles and Au surfaces and polymeric materials. The photosensitive aminoacid monomer linkers can react via chemically and biocompatible to a lot of different micro and nano-surface and then to the protein when they act as a single-step cross-linking reaction using irradiation.
    Type: Application
    Filed: December 11, 2009
    Publication date: December 22, 2011
    Inventors: Arzu Ersoz, Deniz Hur, Filiz Yilmaz, Adil Denizli, Ayca Atilir Ozcan, Sibel Emir Diltemiz, Suzan Yazar, Ozlem Bicen, Sibel Buyuktiryaki, Rustem Kecili, Guner Saka, Tugba Findik
  • Publication number: 20110288145
    Abstract: The present invention relates to the use of L-tryptophan and a peripheral degradation inhibitor of L-tryptophan for the manufacture of a medicament for prevention or therapy of pain, depressions, sleeping disorders and other serotonin dependent diseases of the CNS, wherein L-tryptophan is present in a retarded and the peripheral degradation inhibitor is present in a non-retarded formulation.
    Type: Application
    Filed: August 12, 2005
    Publication date: November 24, 2011
    Inventor: Joachim Kamprad
  • Publication number: 20110281879
    Abstract: The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them.
    Type: Application
    Filed: January 12, 2011
    Publication date: November 17, 2011
    Applicant: ViroBay, Inc.
    Inventor: Craig Mossman
  • Publication number: 20110275782
    Abstract: New bioresorbable polymers are synthesized from monomer analogs of natural metabolites In particular, polymers are polymerized from analogs of amino acids that contribute advantageous synthesis, processing and material properties to the polymers prepared therefrom, including particularly advantageous degradation profiles
    Type: Application
    Filed: September 16, 2009
    Publication date: November 10, 2011
    Applicant: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY
    Inventors: Joachim B. Kohn, Durgadas Bolikal
  • Publication number: 20110263505
    Abstract: The invention relates to a whey protein hydrolysate, in particular a hydrolysate consisting of whey protein enriched with ?-lactalbumin and ?-lactalbumin, and the use thereof for producing pharmaceuticals, anti-hypertensive agents, food supplements, foodstuffs and animal feed, and to pharmaceuticals, anti-hypertensive agents, food supplements, foodstuffs and animal feed produced in this manner. The whey protein hydrolysate according to the invention, which has an ACE inhibiting and anti-hypertensive action, contains a physiologically active quantity of at least one peptide containing tryptophan, preferably at least one of the bio-active dipeptides Ile-Trp and Trp-Leu, and can be obtained by the extensive hydrolysis of whey protein isolates or of pure ?-lactalbumin.
    Type: Application
    Filed: July 2, 2009
    Publication date: October 27, 2011
    Applicant: TECHNISCHE UNIVERSITÄT DRESDEN
    Inventors: Thomas Henle, Andreas Deussen, Melanie Martin
  • Publication number: 20110236395
    Abstract: Inhibitors of matrix metalloproteinase 2 are used to treat or prevent a fibrotic disorder of the posterior capsule of the eye, for example posterior capsule opacification (PCO), or of a tissue or structure of the eye other than the lens or capsular bag.
    Type: Application
    Filed: September 9, 2009
    Publication date: September 29, 2011
    Applicant: UNIVERSITY OF EAST ANGLIA
    Inventors: Ian Michael Wormstone, Lucy Dawes, Julie Ann Eldred, Dylan Edwards, Lisa Hodgkinson
  • Publication number: 20110224184
    Abstract: The present invention provides pharmaceutical compositions comprising substituted 1,4 naphthoquinones that are effective in preventing oligomerization of beta amyloid and subsequent pathologies associated with amyloid fibrils. These compositions are useful for the treatment of disease involving amyloidogenesis including neurodegenerative diseases such as Alzheimer's Disease or senile dementia. Particularly effective compositions comprise 1,4 naphthoquinones substituted with an amino acid residue selected from a heterocyclic or aromatic amino acid.
    Type: Application
    Filed: September 6, 2009
    Publication date: September 15, 2011
    Applicant: RAMOT AT TEL AVIV UNIVERSITY LTD.
    Inventors: Roni Scherzer, Ehud Gazit, Daniel Segal
  • Publication number: 20110183913
    Abstract: There is provided a gelator that is capable of forming a gel by an extremely small amount of addition in a wide pH range from acidic to alkaline regions, and a gel having high environmental compatibility, biocompatibility, and biodegradability. A gelator comprising: a lipid peptide of Formula (1) wherein R1 is a C9-23 aliphatic group, R2 is a hydrogen atom or a C1-4 alkyl group optionally having a C1-2 branched chain, R3 is a —(CH2)n-X group, n is a number from 1 to 4, and X is an amino group, a guanidino group, a —CONH2 group, or a 5-membered ring optionally having 1 to 3 nitrogen atoms, a 6-membered ring optionally having 1 to 3 nitrogen atoms, or a fused heterocycle including a 5-membered ring and a 6-membered ring that optionally has 1 to 3 nitrogen atoms); or a pharmaceutically usable salt of the lipid peptide.
    Type: Application
    Filed: June 19, 2009
    Publication date: July 28, 2011
    Applicant: NISSAN CHEMICAL INDUSTRIES, LTD.
    Inventors: Misao Miyamoto, Nobuhide Miyachi, Takehisa Iwama
  • Publication number: 20110178087
    Abstract: The present invention provides novel compounds and pharmaceutical compositions thereof, as well as methods for using the compounds and pharmaceutical compositions for treating tumors. Examples of specific tumor types that the compounds may be used to treat include, but are not limited to sarcomas, melanomas, neuroblastomas, carcinomas (including but not limited to lung, renal cell, ovarian, liver, bladder, and pancreatic carcinomas), and mesotheliomas.
    Type: Application
    Filed: March 30, 2011
    Publication date: July 21, 2011
    Applicant: Compass Pharmaceuticals LLC.
    Inventors: David Kanne, John Ward, Gary Look, X. Michael Wang, Diva Chan, Tina Lee, Donald R. James, Richard Gless, John Schullek, Charles Vacin
  • Publication number: 20110171690
    Abstract: To provide ACE inhibitory peptides which can effectively inhibit ACE by a small amount of ingestion and have no fear of causing side effects and which can be orally ingested easily during daily life by persons having high blood pressure, and compositions comprising the peptides. The peptides represented by the following structural formulae (1) to (9), and salts thereof are provided.
    Type: Application
    Filed: February 6, 2009
    Publication date: July 14, 2011
    Applicant: KIKKOMAN CORPORATION
    Inventors: Takeharu Nakahara, Riichiro Uchida, Hitomi Aota, Katsutoshi Sugimoto, Takuya Sato
  • Publication number: 20110158947
    Abstract: We disclose agents useful in the treatment of diseases or conditions that would benefit from improved muscle function and including pharmaceutical compositions and diagnostic tests for determining the predisposition of a subject, in particular a male subject, to cardiovascular disease.
    Type: Application
    Filed: July 9, 2009
    Publication date: June 30, 2011
    Inventor: Aleksandar Jovanovic
  • Publication number: 20110152321
    Abstract: The present invention is directed to novel bicyclic derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by DPP-1.
    Type: Application
    Filed: December 16, 2010
    Publication date: June 23, 2011
    Inventors: Edward C. Lawson, Dennis J. Hlasta, Shyamali Ghosh, Renee L. DesJarlais, Carsten Schubert
  • Patent number: 7901793
    Abstract: Provided are an organic light-emitting compound of Formula 1 and an organic light-emitting device using the organic light-emitting compound: where Ar, R1, R2, R3, R4, and R5 are the same as defined in the detailed description. The organic light-emitting device manufactured using the organic light-emitting compound has a low turn-on voltage and high efficiency and color purity.
    Type: Grant
    Filed: September 22, 2006
    Date of Patent: March 8, 2011
    Assignee: Samsung Mobile Display Co., Ltd.
    Inventors: Myeong-Suk Kim, Byoung-Ki Choi, Jong-Jin Park, Tae-Yong Noh, Lyong-Sun Pu, Jhun-Mo Son, Woon-Jung Paek, Young-Mok Son, O-Hyun Kwon, Che-Un Yang, Shinichiro Tamura
  • Patent number: 7897788
    Abstract: The invention relates to indol-1-yl-acetic acid derivatives and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more of those compounds and methods of treatment comprising administration of said compounds.
    Type: Grant
    Filed: March 8, 2005
    Date of Patent: March 1, 2011
    Assignee: Actelion Pharmaceutical Ltd.
    Inventors: Anja Fecher, Heinz Fretz, Kurt Hilpert, Markus Riederer
  • Publication number: 20110033393
    Abstract: The present invention relates to hydrazone compounds of Formula I: and pharmaceutically acceptable salts and stereoisomers thereof, wherein R1, R2, R3, R4, L1, and L2 are defined as set forth in the specification. The invention is also directed to the use of compounds of Formula I as inhibitors of TRPM5 protein.
    Type: Application
    Filed: May 12, 2010
    Publication date: February 10, 2011
    Inventors: Philip STEIN, Robert DAINES, Dennis SPROUS, Harold O'GRADY
  • Patent number: 7879791
    Abstract: A mechanism of macrophage-induced T cell suppression is the selective elimination of tryptophan and/or increase in one or more tryptophan metabolites within the local macrophage microenvironment. Studies demonstrate that expression of IDO can serve as a marker of suppression of T cell activation, and may play a significant role in allogeneic pregnancy and therefore other types of transplantation, and that inhibitors of IDO can be used to activate T cells and therefore enhance T cell activation when the T cells are suppressed by pregnancy, malignancy or a virus such as HIV. Inhibiting tryptophan degradation (and thereby increasing tryptophan concentration while decreasing tryptophan metabolite concentration), or supplementing tryptophan concentration, can therefore be used in addition to, or in place of, inhibitors of IDO.
    Type: Grant
    Filed: November 21, 2006
    Date of Patent: February 1, 2011
    Assignee: Medical College of Georgia Research Institute, Inc.
    Inventors: David Munn, Andrew Mellor
  • Patent number: RE43632
    Abstract: The invention relates to compounds of formula: wherein R1 is selected from the group consisting of fatty acid acyl groups of 12 to 30 carbon atoms and fatty alcohol groups of 12 to 30 carbon atoms, and wherein R2 is selected from the group consisting of H, fatty acid acyl of 12 to 30 carbon atoms and fatty alcohol groups of 12 to 30 carbon atoms, the same as or different from R1, and the residue of a nutrient, drug, or other bioactive compound, and to the use of these compounds to deliver drugs and other bioactive compounds.
    Type: Grant
    Filed: May 1, 1996
    Date of Patent: September 4, 2012
    Assignee: Scarista, Ltd.
    Inventors: David B. Horrobin, Sherri Clarkson, legal representative, Mehar Manku, Philip Knowles, Peter Redden, Andrea Pitt, Paul Bradley, Paul Wakefield, Austin McMordie